

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/111339 A1

(51) International Patent Classification:

C07D 471/14 (2006.01) A61K 31/519 (2006.01)
C07D 487/04 (2006.01) A61K 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/056671

(22) International Filing Date:

20 November 2024 (20.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/601,453 21 November 2023 (21.11.2023) US

(71) Applicant: **858 THERAPEUTICS, INC.** [US/US]; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US).

(72) Inventors: **VEAL, James M.**; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US). **STAFFORD, Jeffrey A.**; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US). **BAIN, Gretchen W.**; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US). **BELL-MCGUINN, Katherine M.**; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US). **HOLLERAN, John P.**; 3115 Merryfield Row, Suite 110, San Diego, California 92121 (US).

(74) Agent: **CLARK, David** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF CANCER WITH A PARG INHIBITOR

CRC for Inhibition of PARG Activity




FIGURE 1

(57) Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a PARG inhibitor. Some embodiments comprise combination therapy featuring the PARG inhibitor with at least one additional oncology therapeutic agent.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*